WIB22: Leading NK cell researcher reflects on roots in Iran, the UK and Texas
This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.
In a small but widely-cited 11-person study published in NEJM in 2020, seven patients saw signs of their cancer completely go away after getting a new therapy made from natural killer cells. The study was one of the earliest to provide clinical proof that the experimental treatment method had promise.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.